Status: Recruiting
MSC EVs in Dystrophic Epidermolysis Bullosa
INVESTIGATIONAL PRODUCT: AGLE-102 is an allogeneic extracellular vesicle (EV) product derived from normal donor mesenchymal stem cells (MSCs). INDICATION AND RATIONALE: The aim of the study is to assess the safety and efficacy of AGLE-102 in the treatment of lesions in subjects with Epidermolysis Bullosa (EB). STUDY DESIGN: This is a phase 1/2A, randomized, multi-center, study to assess the effectiveness and safety of AGLE-102 on lesions in subjects with EB.
Participants needed: 8
Trial details
Phase: Phase 1, Phase 2Age: 6+Biological sex: AllType: InterventionalSponsor: Aegle TherapeuticsUpdated: Jun 25, 2025Locations: 3
Eligibility criteria
Subjects must be 6 months or older at screening. [+6]
Concomitant treatment at the time of screening or at any time during the study o... [+15]